Publication date: Available online 28 July 2016
Source:Cancer Cell
Author(s): Fabrizio Miranda, David Mannion, Shujuan Liu, Yiyan Zheng, Lingegowda S. Mangala, Clara Redondo, Sandra Herrero-Gonzalez, Ruoyan Xu, Charlotte Taylor, Donatien Fotso Chedom, Mohammad Karaminejadranjbar, Ashwag Albukhari, Dahai Jiang, Sunila Pradeep, Cristian Rodriguez-Aguayo, Gabriel Lopez-Berestein, Eidarus Salah, Kamal R. Abdul Azeez, Jonathan M. Elkins, Leticia Campo, Kevin A. Myers, Daniel Klotz, Serena Bivona, Sunanda Dhar, Robert C. Bast, Hideyuki Saya, Hwan Geun Choi, Nathanael S. Gray, Roman Fischer, Benedikt M. Kessler, Christopher Yau, Anil K. Sood, Takeshi Motohara, Stefan Knapp, Ahmed Ashour Ahmed
The adipocyte-rich microenvironment forms a niche for ovarian cancer metastasis, but the mechanisms driving this process are incompletely understood. Here we show that salt-inducible kinase 2 (SIK2) is overexpressed in adipocyte-rich metastatic deposits compared with ovarian primary lesions. Overexpression of SIK2 in ovarian cancer cells promotes abdominal metastasis while SIK2 depletion prevents metastasis in vivo. Importantly, adipocytes induce calcium-dependent activation and autophosphorylation of SIK2. Activated SIK2 plays a dual role in augmenting AMPK-induced phosphorylation of acetyl-CoA carboxylase and in activating the PI3K/AKT pathway through p85α-S154 phosphorylation. These findings identify SIK2 at the apex of the adipocyte-induced signaling cascades in cancer cells and make a compelling case for targeting SIK2 for therapy in ovarian cancer.
Graphical abstract
Teaser
Miranda et al. show that in serous ovarian cancer SIK2 is overexpressed in adipocyte-rich metastatic deposits compared with primary lesions. Adipocytes induce calcium-dependent activation and autophosphorylation of SIK2, which drives tumor cell survival and metabolism. SIK2 depletion prevents metastasis in vivo.from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2amX6PS
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου